← Human Trials & Peer-Reviewed Studies
Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone.
Plain-language guide to PMID 21619701 (2011): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 154 girls.
Key Facts
- PMID
- 21619701
- Journal
- BMC pediatrics
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Taback SP et al. (2 authors)
- DOI
- 10.1186/1471-2431-11-49
- Registered trial
- NCT00191113
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
There are limited long-term randomized controlled trials of growth hormone (GH) supplementation to adult height and few published reports of the health-related quality of life (HRQOL) following treatment.
Who Took Part
According to the abstract, 154 girls were involved.
The age groups tagged for this paper are children, teenagers and young adults, women only.
Patients were eligible for the follow-up study if they were at least 16 years old at the time of follow-up.
The instrument used to study HRQOL was the SF-36, summarized into physical and mental component scales (PCS and MCS); higher scores indicate better HRQOL.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
What Was Measured
The subject headings attached to it are Estrogens, Human Growth Hormone, Puberty, Quality of Life, Recombinant Proteins and Turner Syndrome.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 154 girls.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (BMC pediatrics), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.